Large scale follow-up research study: SneakPeek® Early Gender DNA Test 99.9% accurate for fetal sex by live-birth confirmation
International Journal of Pregnancy & Child Birth – December 29, 2020
Early fetal sex determination has become more prevalent among parents interested in planning for their unborn child. Current advances in non-invasive prenatal testing (NIPT) have facilitated this desire with safe and efficient methods such as the SneakPeek® Early Gender DNA Test (“SneakPeek”).
Motivations behind Early Fetal Sex Determination
Clinics in Mother and Child Health – October 14, 2020
There are many momentous events that accompany the journey of childbirth, one of which is the discovery of the fetus’s sex. What most expecting families are unaware of is that in addition to the traditional approaches, there exists newer developed technologies that allow for an earlier determination of the fetus’s sex.
Reported Benefits of Early Fetal Sex Determination
International Journal of Pregnancy & Child Birth – June 3, 2020
In order to assess the perceived benefits of early fetal sex determination, Gateway Genomics constructed a study in which postpartum women provided insight into the effect of the early gender test on their pregnancy journey. Results from the survey confirm that early fetal sex determination does confer various benefits to the childbearing process.
Accurate Fetal Sex Determination from Maternal Blood at 8 Weeks Gestation
International Journal of Pregnancy & Child Birth – July 8, 2019
Prior studies have shown that SneakPeek® Early Gender Test can accurately determine fetal sex as early as 9 weeks gestation using a qPCR-based assay. The purpose of this study was to evaluate the clinical performance of SneakPeek® for noninvasive prenatal testing (NIPT) to determine fetal sex at an earlier time point: 8 weeks gestation.
Self-Collection of Maternal Blood for Fetal Sex Determination Using Cell-Free DNA
Journal of Pregnancy & Child Health – March 1, 2019
SneakPeek® Early Gender Test (Gateway Genomics) is a qPCR-based assay that utilizes a microvolume of maternal plasma to determine the fetal sex as early as 9 weeks gestation. In this study, we aimed to evaluate the accuracy of SneakPeek Early Gender Test for fetal sex determination in self-collected maternal blood samples.
Early Fetal Sex Determination using Cell-Free DNA in Micro-Volume of Maternal Plasma
Journal of Pregnancy & Child Health – December 2, 2017
A qPCR-based assay, SneakPeek® Early Gender Test (Gateway Genomics), has been developed to determine fetal sex as early as 9 weeks gestation using a micro-volume of maternal plasma. The purpose of this study was to assess the clinical performance of SneakPeek for noninvasive prenatal testing (NIPT) of fetal sex.